ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

SNG Synairgen Plc

4.675
0.00 (0.00%)
26 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4.675 4.36 4.99 - 60,335 08:00:27
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -17.65M -0.0876 -0.53 9.41M
Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 4.68p. Over the last year, Synairgen shares have traded in a share price range of 3.65p to 10.62p.

Synairgen currently has 201,374,975 shares in issue. The market capitalisation of Synairgen is £9.41 million. Synairgen has a price to earnings ratio (PE ratio) of -0.53.

Synairgen Share Discussion Threads

Showing 33151 to 33169 of 99175 messages
Chat Pages: Latest  1327  1326  1325  1324  1323  1322  1321  1320  1319  1318  1317  1316  Older
DateSubjectAuthorDiscuss
10/10/2020
08:26
I'm thinking when Prince Charles got Covid he got better quite quickly and without any fuss.I wonder what treatment he was given...?Could the Knighthood be the reward?
the real capitalcity
10/10/2020
08:21
Thanks to Everton222 on LSE https://www.southampton.ac.uk/news/2020/10/stephen-holgate-queens-birthday-honours.pageExtract from the link. One of those developments was Synairgen – a spin out company created by the three of them that Professor Holgate says explains, was based on understanding why patients with lung disease are so vulnerable to respiratory viruses, like the common cold, and how this could be rectified."By finding the abnormality as a defect in the production of a crucial protective substance (interferon beta), we were able to develop a treatment that could replace the missing molecule in the anti-viral immune response. Synairgen is developing inhaled interferon beta showing benefit in severe asthma and chronic obstructive pulmonary disease and, most importantly, in hospitalised patients with COVID-19," he concluded.
blakieboy7
10/10/2020
00:29
5 day old account alert!
nmulm
09/10/2020
21:07
You got to worry when all the nutters join in!
dave444
09/10/2020
20:50
...expect some very brilliant and big news on Monday- it’s going North, at last we will see this used globally 🚀🚀🚀👍 7468;🇧ԅ67;😉
strongbuy
Chat Pages: Latest  1327  1326  1325  1324  1323  1322  1321  1320  1319  1318  1317  1316  Older